Ovintiv Inc. (OVV)

Negative revenue growth while VET stands at 20.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.

Negative gross profit growth while VET is at 82.61%. Joel Greenblatt would examine cost competitiveness or demand decline.

Negative EBIT growth while VET is at 59.29%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Negative operating income growth while VET is at 59.29%. Joel Greenblatt would press for urgent turnaround measures.

Negative net income growth while VET stands at 35.12%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

Negative EPS growth while VET is at 36.84%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Negative diluted EPS growth while VET is at 36.84%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.

Negative OCF growth while VET is at 67.36%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.

FCF growth under 50% of VET's 323.67%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.

Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.

Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.

Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.

Negative 10Y OCF/share CAGR while VET stands at 44.76%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.

Negative 5Y OCF/share CAGR while VET is at 55.99%. Joel Greenblatt would question the firm’s operational model or cost structure.

Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.

Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.

Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.

Negative equity/share CAGR over 10 years while VET stands at 77.77%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.

Negative 5Y equity/share growth while VET is at 14.36%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.

Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.

Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.

Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.

Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.

Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.